<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Medicus Pharma Ltd. — News on 6ix</title>
<link>https://6ix.com/company/medicus-pharma-ltd</link>
<description>Latest news and press releases for Medicus Pharma Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 17 Apr 2026 11:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/medicus-pharma-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d769ac51cc36e47533beed.webp</url>
<title>Medicus Pharma Ltd.</title>
<link>https://6ix.com/company/medicus-pharma-ltd</link>
</image>
<item>
<title>Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-submits-orphan-drug-designation-application-to-us-fda-for-skinjectr-in-gorlin-syndrome</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-submits-orphan-drug-designation-application-to-us-fda-for-skinjectr-in-gorlin-syndrome</guid>
<pubDate>Fri, 17 Apr 2026 11:30:00 GMT</pubDate>
<description>Targets rare, high-burden genetic condition with no approved therapies; advances non-surgical treatment strategy for recurrent basal cell carcinomaPHILADELPHIA, April 17, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced the submission of an Orphan Drug Designation (ODD) application to the U.S. Food</description>
</item>
<item>
<title>Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-to-present-new-teverelix-data-at-aace-2026-demonstrating-long-acting-hormone-suppression</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-to-present-new-teverelix-data-at-aace-2026-demonstrating-long-acting-hormone-suppression</guid>
<pubDate>Wed, 15 Apr 2026 11:30:00 GMT</pubDate>
<description>Updated Safety, Efficacy, and Clinical Data Supports Teverelix as Potentially the First Long-Acting Injectable GnRH Antagonist Across Multiple Indications in Women’s HealthPHILADELPHIA, April 15, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced it will present new Phase 1 clinical data on Teverelix</description>
</item>
<item>
<title>New to The Street Signs Medicus Pharma Ltd. (NASDAQ:MDCX) to Transformational 12-Part National Media Series Highlighting SkinJect(TM) and Teverelix(R) Platforms</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/new-to-the-street-signs-medicus-pharma-ltd-nasdaqmdcx-to-transformational-12-part-national-media-series-highlighting-skinjecttm-and-teverelixr-platforms</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/new-to-the-street-signs-medicus-pharma-ltd-nasdaqmdcx-to-transformational-12-part-national-media-series-highlighting-skinjecttm-and-teverelixr-platforms</guid>
<pubDate>Tue, 07 Apr 2026 12:30:00 GMT</pubDate>
<description>NEW YORK CITY, NY / ACCESS Newswire / April 7, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX), a precision-guided biotech and life sciences company advancing innovative therapeutic platforms, has entered into a 12-part, one-year strategic media agreement ...</description>
</item>
<item>
<title>Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-submits-optimized-phase-2-study-protocol-to-us-fda-for-teverelix-in-acute-urinary-retention</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-submits-optimized-phase-2-study-protocol-to-us-fda-for-teverelix-in-acute-urinary-retention</guid>
<pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
<description>Mechanism-Driven Study Design Focused on Capital Efficiency and Accelerated Development for Near-Term Value Creation, Addressing a $2 Billion Potential Target</description>
</item>
<item>
<title>Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-ltd-clarifies-positive-skinject-phase-2-dataset</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-ltd-clarifies-positive-skinject-phase-2-dataset</guid>
<pubDate>Wed, 01 Apr 2026 11:30:00 GMT</pubDate>
<description>Provides guidance on interpretation of Topline dataset and confirms focus on drug-driven efficacy in non-melanoma skin cancerPHILADELPHIA, April 01, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today issued a clarification regarding previously reported topline results from its Phase 2 clinical study of SKNJCT-</description>
</item>
<item>
<title>Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-reports-kol-validation-of-skinject-phase-2-data-of-80percent-overall-response-rate</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-reports-kol-validation-of-skinject-phase-2-data-of-80percent-overall-response-rate</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Dr. Babar Rao highlights clinically meaningful outcomes with majority of lesions potentially avoiding immediate surgery in non-melanoma Skin Cancer</description>
</item>
<item>
<title>Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-business-update-call-to-highlight-80percent-overall-response-rate-orr-in-phase-2-skinject-study-and-agentic-ai-enabled-drug-development-plan</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-business-update-call-to-highlight-80percent-overall-response-rate-orr-in-phase-2-skinject-study-and-agentic-ai-enabled-drug-development-plan</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>200µg Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin Cancer</description>
</item>
<item>
<title>Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-reports-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-reports-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>Advances Clinical Pipeline Across Dermatology, Urology, Oncology and strengthens Capital Base to support Phase 2 Programs PHILADELPHIA, PA / ACCESS Newswire /</description>
</item>
<item>
<title>Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-to-discuss-positive-skinjectr-phase-2-topline-results-in-fireside-chat-hosted-by-brookline-capital-markets-biotechnology-equity-research-analyst</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-to-discuss-positive-skinjectr-phase-2-topline-results-in-fireside-chat-hosted-by-brookline-capital-markets-biotechnology-equity-research-analyst</guid>
<pubDate>Wed, 18 Mar 2026 11:30:00 GMT</pubDate>
<description>Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, PA / ACCESS Newswire / March 18, 2026 / Medicus Pharma Ltd. ...</description>
</item>
<item>
<title>Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-announces-skinjectr-phase-2-principal-investigator-and-key-opinion-leader-kol-babar-k-rao-md-faad-to-provide-clinical-interpretation-of-positive-data-during-business-update-webcast-on-march-26</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-announces-skinjectr-phase-2-principal-investigator-and-key-opinion-leader-kol-babar-k-rao-md-faad-to-provide-clinical-interpretation-of-positive-data-during-business-update-webcast-on-march-26</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical</description>
</item>
<item>
<title>Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-ltd-to-participate-in-the-longwood-miami-ceo-forum-4</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-ltd-to-participate-in-the-longwood-miami-ceo-forum-4</guid>
<pubDate>Tue, 10 Mar 2026 11:30:00 GMT</pubDate>
<description>Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled Drug Development Strategy PHILADELPHIA, PA / ACCESS Newswire / March 10, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the ...</description>
</item>
<item>
<title>Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-provides-interpretation-of-positive-phase-2-skinjecttm-dataset</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-provides-interpretation-of-positive-phase-2-skinjecttm-dataset</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>The Company Reported 73% Clinical Clearance in the 200-µg cohort at Day 57 PHILADELPHIA, March 09, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX)</description>
</item>
<item>
<title>Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-reports-positive-phase-2-sknjct-003-topline-data-observing-73percent-clinical-clearance-and-40percent-histological-clearance-cr-at-day-57-in-200mg-cohort-8</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-reports-positive-phase-2-sknjct-003-topline-data-observing-73percent-clinical-clearance-and-40percent-histological-clearance-cr-at-day-57-in-200mg-cohort-8</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>The Company is expected to finalize the Clinical Study Report (CSR) in Q2 2026 to support planned end of Phase 2 (EOP2) meeting with the FDA PHILADELPHIA,</description>
</item>
<item>
<title>Medicus Pharma To Participate in the 38th Annual Roth Conference</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-to-participate-in-the-38th-annual-roth-conference</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-to-participate-in-the-38th-annual-roth-conference</guid>
<pubDate>Tue, 03 Mar 2026 12:30:00 GMT</pubDate>
<description>Company Exec. Chairman & CEO in a fireside chat is expected to highlight the role of Skinject in an autosomal dominant rare disease, AI-enabled drug development strategy and partnering readinessPHILADELPHIA, March 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce it will be participating</description>
</item>
<item>
<title>Medicus Pharma on Bloomberg World</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-on-bloomberg-world</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-on-bloomberg-world</guid>
<pubDate>Thu, 12 Feb 2026 12:30:00 GMT</pubDate>
<description>Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller PHILADELPHIA, PA / ACCESS Newswire / February 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life ...</description>
</item>
<item>
<title>New to The Street Signs Six-Part Media Series Featuring Medicus Pharma Ltd.</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/new-to-the-street-signs-six-part-media-series-featuring-medicus-pharma-ltd</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/new-to-the-street-signs-six-part-media-series-featuring-medicus-pharma-ltd</guid>
<pubDate>Tue, 10 Feb 2026 13:30:00 GMT</pubDate>
<description>NEW YORK CITY, NY / ACCESS Newswire / February 10, 2026 /New to The Street, the nationally syndicated, long-form television and digital media platform, today announced it has signed a six-part media series with Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" ...</description>
</item>
<item>
<title>Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-receives-fda-study-may-proceed-clearance-for-teverelixr-phase-2b-study-in-advanced-prostate-cancer-patients-with-high-cardiovascular-risk</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-receives-fda-study-may-proceed-clearance-for-teverelixr-phase-2b-study-in-advanced-prostate-cancer-patients-with-high-cardiovascular-risk</guid>
<pubDate>Tue, 10 Feb 2026 05:00:00 GMT</pubDate>
<description>The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and a first in class product</description>
</item>
<item>
<title>Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-marks-nasdaq-anniversary-with-opening-bell-ceremony</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-marks-nasdaq-anniversary-with-opening-bell-ceremony</guid>
<pubDate>Fri, 23 Jan 2026 12:30:00 GMT</pubDate>
<description>PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and ...</description>
</item>
<item>
<title>Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-ltd-announces-amendment-to-lifearc-license-improving-teverelixr-long-term-economic-and-development-profile</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-ltd-announces-amendment-to-lifearc-license-improving-teverelixr-long-term-economic-and-development-profile</guid>
<pubDate>Thu, 22 Jan 2026 05:00:00 GMT</pubDate>
<description>Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control The Company is developing</description>
</item>
<item>
<title>Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026</title>
<link>https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-ltd-celebrates-one-year-on-nasdaq-with-opening-bell-ceremony-on-january-22-2026</link>
<guid isPermaLink="true">https://6ix.com/company/medicus-pharma-ltd/news/medicus-pharma-ltd-celebrates-one-year-on-nasdaq-with-opening-bell-ceremony-on-january-22-2026</guid>
<pubDate>Tue, 20 Jan 2026 12:30:00 GMT</pubDate>
<description>The Company enters 2026 with Multiple Phase 2 Catalysts, AI-enabled drug development strategy, and regulatory optionality as SKNJCT-003 study approaches database lock, topline clinical data readout and partnering readinessPHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is p</description>
</item>
</channel>
</rss>